MiniMed Group, Inc.

MiniMed Group, Inc., a spin-off from Medtronic plc, is a global medical technology company developing, manufacturing, and marketing integrated diabetes management solutions including automated insulin delivery (AID) systems, continuous glucose monitors (CGMs), smart insulin pens, and dosing algorithms. As the only company commercializing all components of AID systems on a unified platform, it serves insulin-dependent patients worldwide, with products like the MiniMed 780G system achieving superior Time in Range (TIR) outcomes. For fiscal year 2025 ended April 25, 2025, the Company reported $2.7 billion in revenue (up from $2.5 billion in FY2024), primarily from consumables (80%), OUS sales (67%), and servicing over 640,000 pump users in 80 countries; Adjusted EBITDA was $253 million (9% margin) despite a $198 million net loss. In the six months ended October 24, 2025, revenue reached $1.5 billion with Adjusted EBITDA of $128 million. The Company is pursuing an IPO of 28 million shares (90.03% post-IPO ownership retained by Medtronic), with proceeds partly retained ($350 million cash on hand) for general corporate purposes and the rest to repay intercompany debt to Medtronic. This separation enables focused innovation in hands-free AID, global expansion in a $18 billion+ market growing double-digits, leveraging 40+ years of legacy, 2,500+ patents, and a pipeline including MiniMed Flex pump and Vivera algorithm, positioning MiniMed for profitable growth amid rising diabetes prevalence (589 million PWD globally).

Key Takeaways